Global Gonorrhea Therapeutics Market 2017-2021
About Gonorrhea Therapeutics
Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.
Technavio’s analysts forecast the global gonorrhea therapeutics market to grow at a CAGR of 2.88% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global gonorrhea therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Gonorrhea Therapeutics Market 2017-2021
Technavio recognizes the following companies as the key players in the global gonorrhea therapeutics market: Bharat Pharmaceuticals, GlaxoSmithKline, Merck, and Pfizer
Other Prominent Vendors in the market are: Alopexx Pharmaceuticals, AstraZeneca, Cempra, Debiopharm Group, and Melinta Therapeutics.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea . Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.”
According to the report, one of the major drivers for this market is Rising prevalence of disease. The rising prevalence of gonorrhea is a major health concern globally. As per the CDC, approximately 700,000 new cases of gonorrhea are identified each year in the US. In 2009, the CDC reported 301,174 cases of gonorrhea, demonstrating an incidence rate of 99.1 cases per 100,000 US population. The disease follows chlamydial infection as the second most common STD in the US. The rising prevalence rate of gonorrhea is due to several factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and the financial constraints that limit the abilities of public healthcare officials to check the disease pattern precisely.
Further, the report states that one of the major factors hindering the growth of this market is Emergence of antibiotic-resistant gonococcal strain. The global gonorrhea therapeutics market is familiar with antibiotic resistance in gonorrheal strains. In 2007, the emergence of fluoroquinolone-resistant Neisseria gonorrhoeae prompted the CDC to prohibit the use of fluoroquinolone in the US, leaving cephalosporin as the only treatment option for gonorrheal infection. However, during 2006-2011, the minimum inhibitory concentration (MIC) of cefixime increased in the US and other countries, indicating the decrease in effectiveness of cefixime for treating the gonorrheal infection. In addition, these cefixime-resistant gonococcal strains are likely to develop tetracycline resistance but are susceptible to azithromycin.
Bharat Pharmaceuticals, GlaxoSmithKline, Merck, Pfizer, Alopexx Pharmaceuticals, AstraZeneca, Cempra, Debiopharm Group, and Melinta Therapeutics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook